Drs Ursula A. Matulonis and Akila N. Viswanathan discuss the role of radiation therapy in endometrial cancer, including staging, immunotherapy, and treatment disparities.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999853. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

WEE1 Inhibitors Mediate Antitumor Effects on Endometrial Cancer Through Activation of Innate Immune Responses https://pubmed.ncbi.nlm.nih.gov/38169513/

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/16330675/

Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone for Women With High-Risk Endometrial Cancer (PORTEC-3): Final Results of an International, Open-Label, Multicentre, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/29449189/

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972022/

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/36972026/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

Polymerase ɛ (POLE) Mutations in Endometrial Cancer: Clinical Outcomes and Implications for Lynch Syndrome Testing https://pubmed.ncbi.nlm.nih.gov/25224212/

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/37487144/

Risk Factors and Survival Impact Associated With Documentation of Radiation Therapy Refusal in Patients With Gynecologic Cancer https://pubmed.ncbi.nlm.nih.gov/37657506/